Investor Overview

Corporate Profile


Rocket Pharmaceuticals, Inc. is an emerging, clinical-stage biotechnology company focused on developing first-in-class gene therapy treatment options for rare, undertreated diseases. Rocket’s multi-platform development approach applies the well-established lentiviral virus, which we refer to as LVV, adeno-associated virus, which we refer to as AAV, gene therapy platforms.

Stock Information

NASDAQ | RCKT (Common Stock)

$19.39

 0.51 (2.56%)

High$20.50
Low$19.04
Volume331,842
Market Cap$765,525,092

May 21, 2018  4:00 p.m. ET

Minimum 15 minute delay, Data provided by Nasdaq

Stock chart for: RCKT.O.  Currently trading at $19.39 with a 52 week high of $22.40 and a 52 week low of $3.40.